Sign Up to like & get
recommendations!
1
Published in 2020 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-020-0709-3
Abstract: Cellular immunotherapy has been rapidly evolving and increasingly utilized in the management of relapsed and refractory lymphoma. CD19-specific chimeric antigen receptor T cells (CARTs) have achieved impressive results in pivotal clinical trials. Although CART development…
read more here.
Keywords:
cart;
lymphoma;
cellular immunotherapy;
immunotherapy lymphoma ... See more keywords